logo-loader
viewReNeuron Group PLC

ReNeuron looking at applications of its own technology to deliver virus vaccine

ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they're looking at the potential of an emerging cell technology to help in the fight against the recent virus outbreak.

Hunt also says the current disruption will inevitably lead to delays in the recruitment of patients to trials of its treatments for people with stroke disability and a degenerative eye condition called retinitis pigmentosa. 

Quick facts: ReNeuron Group PLC

Price: 145 GBX

LSE:RENE
Market: LSE
Market Cap: £46.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 posts early losses sparked by rising US coronavirus...

Headlines from the Proactive UK newsroom. FTSE100 posted early losses sparked by rising US coronavirus infections and China’s trade row with the US. The blue-chip index shed 10 points to 6,112. Royal Mail PLC (LON:RMG) is to axe 2,000 jobs or more than 20% of its managerial staff as part...

2 weeks, 6 days ago

2 min read